Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-6036 plus pembrolizumab in previously untreated KRAS G12C-mutated advanced or metastatic NSCLC
NL-OMON53747Phase 2Recruiting
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of divarasib and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Sep 2023; status: recruiting.
02
Drugs
divarasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53747.